OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Biological Therapy is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	106
Evaluation of physicochemical and biological properties of nonreconstituted MYL-1401O vials, reconstituted MYL-1401O suspension in vial, and diluted MYL-1401O suspension in infusion bags (0.9% saline)	52
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	51
Aflibercept biosimilars – so near, yet so far	50
Antibody drug conjugates for glioblastoma: current progress towards clinical use	45
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	39
Biosimilars and access to biologic therapy in immune-mediated diseases	37
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	37
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	37
The endosomal-lysosomal system in ADC design and cancer therapy	31
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	30
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	30
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	30
Signaling new therapeutic opportunities: cytokines in prostate cancer	29
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	29
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	28
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing	27
Correction	27
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	22
Long-acting delivery and therapies for neovascular age-related macular degeneration	22
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	21
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	21
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	21
Correction	20
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	20

Need for a risk-based control strategy for managing glycosylation profile for biosimilar products	19
Strategies for extending the half-life of biotherapeutics: successes and complications	18
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	18
Moving toward personalized approaches in the management of lupus nephritis	18
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	18
Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in u	17
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents	16
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	16
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	16
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	15
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	15
Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe	15
A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers	15
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	15
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	15
Unmet needs in cervical cancer – can biological therapies plug the gap?	15
The nail in psoriatic arthritis: new insights into prognosis and treatment	14
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	14
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	14
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	14
Where do we stand with radioimmunotherapy for acute myeloid leukemia?	13
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy	13
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	13
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	13
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	13
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	13
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	13
Management of proctitis in ulcerative colitis and the place of biological therapies	13
Dynamics of biological markets with multiple biosimilar competitors in the United States	13
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	12
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	12
Recent advances in delivering RNA-based therapeutics to mitochondria	12
Current status of developing tissue engineering vascular technologies	12
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	12
Classification and coding of platelet-rich plasma derived from New Zealand white rabbits for tissue engineering and regenerative medicine applications	12
Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?	12
Biological agents targeting interleukin-13 for atopic dermatitis	12
Emerging peptide-based technology for biofilm control	12
An evaluation of pozelimab for the treatment of CHAPLE disease	11
De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris – a systematic review	11
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	11
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	11
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	11
Bispecific antibodies for the treatment of breast cancer	11
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease	11
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?	11
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	11
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	10
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	10
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	10

Personalizing immunotherapy for renal cell carcinoma: how far have we come?	10
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	10
Belimumab patient profile in Spain: evolution during the last decade and future directions	10
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	10
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	10
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	10
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	10
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease	9
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	9
Clinical management and innovation in fracture non-union	9
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	9
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	9
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	9
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	9
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	9
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	9
Non-traditional approaches for control of antibiotic resistance	9
Treating psoriasis in the elderly: biologics and small molecules	9
Antibody therapeutics for epithelial ovarian cancer	9
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	9
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	9
Hemophilia A gene therapy: current and next-generation approaches	8
Biologics in rectal cancer	8
Sargramostim in acute radiation syndrome	8
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	8
Correction	8
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	8
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	8
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	8
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	8
X-linked myotubular myopathy: an untreated treatable disease	8
Epcoritamab in B-cell malignancies: current status and prospects	8
Prostate cancer immunotherapy	8
Ravulizumab for the treatment of myasthenia gravis	8
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	8
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	8
Rilonacept for the treatment of recurrent pericarditis	8
The global landscape on interchangeability of biosimilars	8
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	8
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	8
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	8
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	7
Belantamab mafodotin in multiple myeloma	7
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	7
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	7
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	7
Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast	7
Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa	7
CAR T cells for solid tumors – developments to watch in 2023	7
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	7
Rotavirus vaccines: progress and new developments	7
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder	7
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies	7
The future of cellular therapy for the treatment of renal cell carcinoma	7
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	7
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	7
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus	7
The future of interleukin gene therapy in head and neck cancers	7
The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?	7
Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy	7